Pharma: Clinic Roundup

 CSL Behring, of Charlotte, N.C., said the first patient was enrolled in the PATH (Polyneuropathy And Treatment with Hezentra) study to evaluate the safety and tolerability of two different doses of subcutaneous immunoglobulin compared to placebo in maintenance treatment of chronic inflammatory demyelinating polyneuropathy (CIDP).